Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) was the recipient of a significant decrease in short interest in May. As of May 15th, there was short interest totalling 3,500 shares, a decrease of 58.8% from the April 30th total of 8,500 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 28,100 shares, the short-interest ratio is presently 0.1 days.
Novozymes A/S Trading Up 0.6%
NVZMY traded up $0.40 during midday trading on Friday, hitting $70.85. 41,132 shares of the company traded hands, compared to its average volume of 34,448. The company has a market capitalization of $33.18 billion, a price-to-earnings ratio of 44.84, a PEG ratio of 3.87 and a beta of 0.92. Novozymes A/S has a 52-week low of $53.95 and a 52-week high of $72.50. The business has a 50 day simple moving average of $63.75 and a two-hundred day simple moving average of $59.72.
Novozymes A/S Increases Dividend
The firm also recently disclosed a dividend, which was paid on Wednesday, April 23rd. Stockholders of record on Monday, April 7th were paid a $0.3758 dividend. This is a positive change from Novozymes A/S's previous dividend of $0.17. The ex-dividend date was Monday, April 7th. Novozymes A/S's dividend payout ratio (DPR) is presently 47.47%.
About Novozymes A/S
(
Get Free Report)
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.
See Also
Before you consider Novozymes A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novozymes A/S wasn't on the list.
While Novozymes A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.